WGU D027 FINAL EXAM ACTUAL 2026/2027 | Advanced
Pathopharmacological Foundations Comprehensive Study
Guide | Questions & Verified Answers | Pass Guaranteed - A+
Graded
Part One: Core Principles of Pharmacology—Pharmacokinetics,
Pharmacodynamics, and Drug Safety
Q1: A 68-year-old patient with atrial fibrillation is prescribed digoxin 0.25 mg daily. The
prescriber explains that steady-state concentration will be reached after approximately
how many doses, given digoxin's half-life of 36 hours?
A. 2-3 days
B. 5-7 days
C. 7-8 days [CORRECT]
D. 10-14 days
Correct Answer: C
,Rationale: Steady-state is reached after 4-5 half-lives. With a 36-hour half-life, 4
half-lives = 144 hours (6 days) and 5 half-lives = 180 hours (7.5 days). Option A is too
short (only 1-2 half-lives), B is slightly underestimated, and D is excessive.
Q2: Which pharmacokinetic parameter best explains why a highly lipophilic drug like
amiodarone has a prolonged duration of action even after discontinuation?
A. Low bioavailability requiring large doses
B. High volume of distribution with extensive tissue binding [CORRECT]
C. Rapid hepatic clearance via Phase II metabolism
D. High renal excretion rate
Correct Answer: B
Rationale: Lipophilic drugs distribute extensively into adipose and muscle tissue (high
Vd), creating a large reservoir that slowly releases drug back into circulation. Option A
doesn't explain prolonged action; C and D would actually shorten duration.
Q3: A patient on warfarin develops a urinary tract infection. Which antibiotic is the
SAFEST choice regarding minimal impact on INR?
,A. Ciprofloxacin
B. Trimethoprim-sulfamethoxazole
C. Nitrofurantoin [CORRECT]
D. Metronidazole
Correct Answer: C
Rationale: Nitrofurantoin has minimal CYP450 interaction and doesn't significantly
affect warfarin metabolism. Ciprofloxacin inhibits CYP1A2 and 3A4; TMP-SMX inhibits
CYP2C9 and displaces warfarin from protein binding; metronidazole potently inhibits
warfarin metabolism—all significantly increase INR.
Q4: In a patient with low albumin due to cirrhosis, which effect on drug
pharmacokinetics would the nurse practitioner expect for a highly protein-bound drug
like phenytoin?
A. Decreased free drug concentration and reduced pharmacologic effect
B. Increased free drug concentration with potential for toxicity [CORRECT]
C. No change in drug distribution due to compensatory mechanisms
, D. Enhanced renal clearance of the bound fraction
Correct Answer: B
Rationale: With low albumin, less drug is protein-bound, increasing the free (active)
fraction. This increases pharmacologic effect and toxicity risk even with "therapeutic"
total drug levels. Option A reverses the correct relationship; C and D are incorrect
physiologically.
Q5: A patient taking phenytoin for seizure control shows subtherapeutic levels despite
good adherence. The patient recently started taking rifampin for TB prophylaxis. What is
the most likely explanation?
A. Rifampin inhibits phenytoin metabolism, causing accumulation
B. Rifampin induces CYP2C9 and CYP2C19, increasing phenytoin clearance [CORRECT]
C. Rifampin displaces phenytoin from albumin binding sites
D. Rifampin competes with phenytoin for renal tubular secretion
Correct Answer: B
Rationale: Rifampin is a potent inducer of multiple CYP450 enzymes including 2C9 and
2C19 (primary phenytoin metabolic pathways), increasing clearance and lowering
Pathopharmacological Foundations Comprehensive Study
Guide | Questions & Verified Answers | Pass Guaranteed - A+
Graded
Part One: Core Principles of Pharmacology—Pharmacokinetics,
Pharmacodynamics, and Drug Safety
Q1: A 68-year-old patient with atrial fibrillation is prescribed digoxin 0.25 mg daily. The
prescriber explains that steady-state concentration will be reached after approximately
how many doses, given digoxin's half-life of 36 hours?
A. 2-3 days
B. 5-7 days
C. 7-8 days [CORRECT]
D. 10-14 days
Correct Answer: C
,Rationale: Steady-state is reached after 4-5 half-lives. With a 36-hour half-life, 4
half-lives = 144 hours (6 days) and 5 half-lives = 180 hours (7.5 days). Option A is too
short (only 1-2 half-lives), B is slightly underestimated, and D is excessive.
Q2: Which pharmacokinetic parameter best explains why a highly lipophilic drug like
amiodarone has a prolonged duration of action even after discontinuation?
A. Low bioavailability requiring large doses
B. High volume of distribution with extensive tissue binding [CORRECT]
C. Rapid hepatic clearance via Phase II metabolism
D. High renal excretion rate
Correct Answer: B
Rationale: Lipophilic drugs distribute extensively into adipose and muscle tissue (high
Vd), creating a large reservoir that slowly releases drug back into circulation. Option A
doesn't explain prolonged action; C and D would actually shorten duration.
Q3: A patient on warfarin develops a urinary tract infection. Which antibiotic is the
SAFEST choice regarding minimal impact on INR?
,A. Ciprofloxacin
B. Trimethoprim-sulfamethoxazole
C. Nitrofurantoin [CORRECT]
D. Metronidazole
Correct Answer: C
Rationale: Nitrofurantoin has minimal CYP450 interaction and doesn't significantly
affect warfarin metabolism. Ciprofloxacin inhibits CYP1A2 and 3A4; TMP-SMX inhibits
CYP2C9 and displaces warfarin from protein binding; metronidazole potently inhibits
warfarin metabolism—all significantly increase INR.
Q4: In a patient with low albumin due to cirrhosis, which effect on drug
pharmacokinetics would the nurse practitioner expect for a highly protein-bound drug
like phenytoin?
A. Decreased free drug concentration and reduced pharmacologic effect
B. Increased free drug concentration with potential for toxicity [CORRECT]
C. No change in drug distribution due to compensatory mechanisms
, D. Enhanced renal clearance of the bound fraction
Correct Answer: B
Rationale: With low albumin, less drug is protein-bound, increasing the free (active)
fraction. This increases pharmacologic effect and toxicity risk even with "therapeutic"
total drug levels. Option A reverses the correct relationship; C and D are incorrect
physiologically.
Q5: A patient taking phenytoin for seizure control shows subtherapeutic levels despite
good adherence. The patient recently started taking rifampin for TB prophylaxis. What is
the most likely explanation?
A. Rifampin inhibits phenytoin metabolism, causing accumulation
B. Rifampin induces CYP2C9 and CYP2C19, increasing phenytoin clearance [CORRECT]
C. Rifampin displaces phenytoin from albumin binding sites
D. Rifampin competes with phenytoin for renal tubular secretion
Correct Answer: B
Rationale: Rifampin is a potent inducer of multiple CYP450 enzymes including 2C9 and
2C19 (primary phenytoin metabolic pathways), increasing clearance and lowering
